Back to mobile site
Get it on Google Play

Regeneron drug shows muscle preservation in GLP-1 weight loss trial

October 1, 2026 11:30 AM EDT Send to a Friend
Regeneron Pharmaceuticals (NASDAQ: REGN) announced results from its Phase 2 COURAGE trial showing that trevogrumab, an anti-myostatin antibody, preserved lean ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login